| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 pri...
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst r...
JP Morgan analyst Eric Joseph maintains Beam Therapeutics (NASDAQ:BEAM) with a Overweight and raises the price target from $...
Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $3...
RBC Capital analyst Luca Issi reiterates Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and maintains $27 price target.
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1...
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
